Literature DB >> 12665411

Emerging trends in the pharmacotherapy of chronic pain.

A N Nitu1, R Wallihan, V Skljarevski, N M Ramadan.   

Abstract

The pharmacotherapy for pain is dominated by conventional analgesics such as the opioids and the non-steroidal anti-inflammatory drugs. Recent advances in the understanding of the mechanisms of pain in general and chronic pain in particular, opened the field of analgesic therapy to newer pharmacological targets, which are aimed at improved efficacy and enhanced tolerability over conventional antipain treatments. Many novel targets are still in preclinical development, but some have made it into human trials and have shown promise. Newer anticonvulsants, new generation cyclooxygenase inhibitors, better tolerated glutamate modulators and balanced serotonin/noradrenaline re-uptake inhibitors are some targets that have shown promise in the clinic. These and other compounds that are in advanced phases of development for chronic pain are reviewed in this paper. It is hoped that the decade of pain control and research will lead us to an arsenal of effective and safe analgesics that will conquer the problem of chronic pain.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12665411     DOI: 10.1517/13543784.12.4.545

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  3 in total

1.  Protein-functionalized PLGA nanoparticles of lamotrigine for neuropathic pain management.

Authors:  Jigar Lalani; Sushilkumar Patil; Atul Kolate; Riddhi Lalani; Ambikanandan Misra
Journal:  AAPS PharmSciTech       Date:  2014-10-30       Impact factor: 3.246

Review 2.  Altered neuronal-glial signaling in glutamatergic transmission as a unifying mechanism in chronic pain and mental fatigue.

Authors:  Elisabeth Hansson; Lars Rönnbäck
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

3.  Deletion of vanilloid receptor 1-expressing primary afferent neurons for pain control.

Authors:  Laszlo Karai; Dorothy C Brown; Andrew J Mannes; Stephen T Connelly; Jacob Brown; Michael Gandal; Ofer M Wellisch; John K Neubert; Zoltan Olah; Michael J Iadarola
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.